13.4 C
Monday, May 20, 2024

€16 million seed injection into immune system activation technology to transform cancer and autoimmune disease treatment

- Advertisement -

Commit Biologics, an Aarhus-based company, has secured €16 million in seed funding led by Bioqube Ventures and Novo Holdings. The company specializes in activating the complement system, a part of the immune system, to treat cancer and autoimmune diseases. Their unique Bispecific Complement Engaging (BiCE™) platform utilizes single domain antibodies to bind to the complement protein C1q, selectively killing target cells. The funding will be used to accelerate the development of the BiCE™ platform, allowing for the creation of highly targeted therapeutics that engage the complement system in a precise manner, potentially revolutionizing cancer and autoimmune disease treatment.

Commit plans to accelerate development of its Bispecific Complement Engaging (BiCE™) platform, which uses single domain antibodies that bind to the complement protein C1q to activate the complement system, a fast-acting and potent part of the innate immune system. BiCE™ is a modular system that can arm antibodies to direct the complement system in a highly targeted way, so that it selectively kills cancer cells or immune cells that drive autoimmune diseases.

Commit is a spin-out from Aarhus University in Denmark, which has built a global reputation as a center of excellence in complement system biology over the last three decades. The Company was initially incubated and supported by the BioInnovation Institute in Denmark.

Krishna Polu, MD, Chief Executive Officer of Commit Biologics, said: “This financing from Novo Holdings and Bioqube Ventures validates our pioneering approach of engaging and activating the complement system for therapeutic purposes. Our BiCE™ platform gives us the ability to engage the complement system so that it attacks targeted cells in a highly selective manner. This platform also means we can use established antibodies, which cuts development times and reduces risk, to develop best-in-class therapeutics. This is a novel way of harnessing the immune system to tackle cancer and autoimmune disease, and we are confident in the tremendous potential it offers.”

Jeroen Bakker, Partner at Novo Holdings, said: “With over 30 years of academic rigor from leaders in the complement field behind it, Commit is now unlocking the potential of the complement system to transform the fight against cancer and autoimmune diseases. The team has an incredible track record of domain expertise, and we look forward to working with them to support them on their journey.”

Roderick Verhelst, Principal at Bioqube Ventures, said: “We believe Commit is doing something truly novel in the field of complement and advancing a technology with a multitude of therapeutic applications. Through its direct engagement of the complement system, this BiCE™ technology is a best-in-class approach for complement activation. The ability to arm conventional antibodies with potent complement activators for the development of targeted cell killing therapeutics is also a very attractive way of accelerating and derisking product development.”

Commit’s uniquely engineered and highly specific approach to triggering the complement system is expected to have a wide therapeutic index and broad applicability. BiCE™ technology is modular and active across multiple tumor-associated and target antigens. This approach to activating the immune system can be used in conjunction with other mechanisms of action, such as T-cell directed therapies or other targeted treatments. While antibody drug conjugates, T-cell engagers and CAR-Ts have made important advances in recent years, these approaches can be limited by toxicities, specific target density considerations, and – with T-cell directed therapies – T-cell exhaustion. The BiCE™ technology can potentially address these limitations to enable the development of effective therapeutic options for the treatment of cancer and autoimmune diseases.

Click to read more funding news.

- Advertisement -
Nurcin Metingil
Nurcin Metingil
A permanent student, a passionate first reader and nowadays doing master’s degree in Publishing Management. Beside these, I am up for games! I have been playing games since I was 6. Now, I am whispering "Business. Business. Numbers. Is this working?"

Related News

Stay Connected


Latest News